AUTHOR=Giangiacomi Francesco , Faggiano Andrea , Cardinale Daniela , Rossi Francesca Gaia , Pollina Alberto , Gherbesi Elisa , Gnan Eleonora , Carugo Stefano , Vicenzi Marco 

TITLE=Case report: Sodium-glucose cotransporter 2 inhibitors induce left ventricular reverse remodeling in anthracycline-related cardiac dysfunction—a case series

JOURNAL=Frontiers in Cardiovascular Medicine

VOLUME=10

YEAR=2023

URL=https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2023.1250185

DOI=10.3389/fcvm.2023.1250185

ISSN=2297-055X

ABSTRACT=<sec><title>Purpose</title><p>To describe the efficacy and safety of sodium-glucose cotransporter 2 inhibitors as a specific treatment for anthracycline-related cardiac dysfunction in a small real-world population.</p></sec><sec><title>Methods</title><p>Seven patients with anthracycline-related cardiac dysfunction were clinically and echocardiographically evaluated before and after the introduction of sodium-glucose cotransporter 2 inhibitors.</p></sec><sec><title>Results</title><p>After a median period of 24 weeks with uninterrupted sodium-glucose cotransporter 2 inhibitors treatment, a significant clinical improvement was observed with at least one New York Heart Association Functional Class (NHYA FC) improvement in all patients (median NYHA FC: I vs. III, <italic>p</italic> &lt; 0.010). A noteworthy left ventricular reserve remodeling (median left ventricular end diastolic volume indexed: 53 vs. 82.5 ml/m<sup>2</sup>, <italic>p</italic> = 0.018; median left ventricular ejection fraction: 50% vs. 40%, <italic>p</italic> = 0.17) was also observed. Sodium-glucose cotransporter 2 inhibitors therapy was well tolerated by every patients; no cases of discontinuation or relevant side effects were observed.</p></sec><sec><title>Conclusion</title><p>Sodium-glucose cotransporter 2 inhibitors induce a significant clinical improvement and left ventricular reserve remodeling in patients affected by anthracycline-related cardiac dysfunction.</p></sec>